Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Flibanserin as pharmacological therapy of inhibited sexual desire in women

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Kirurgisk behandling ved kvindelig infertilitet

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dopaminergic drugs in the treatment of depression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vaccination Against Herpes Zoster

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Surfactant therapy of respiratory distress syndrome

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. DBCG Kvalitetsdatabase for Brystkræft – resumé af årsrapport 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  1. Hyperseksualitet

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  2. Sexual Health and Dysfunction in Patients With Rheumatoid Arthritis: A Cross-sectional Single-Center Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.

Bidragets oversatte titelFlibanserin as pharmacological therapy of inhibited sexual desire in women
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind179
Udgave nummer7
ISSN0041-5782
StatusUdgivet - 13 feb. 2017

    Forskningsområder

  • Benzimidazoles/pharmacokinetics, Female, Humans, Libido/drug effects, Serotonin 5-HT2 Receptor Antagonists/pharmacology, Serotonin Receptor Agonists/pharmacology, Sexual Dysfunctions, Psychological/drug therapy

ID: 55813334